Stock Market & Financial Investment News

Glaxo, Theravance announce Japanese approval for Anoro ElliptaGlaxoSmithKline (GSK) and Theravance (THRX) announced Friday that the Japanese Ministry of Health, Labour and Welfare has approved Anoro Ellipta for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases. Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $10M to GSK following MHLW approval of UMEC/VI in Japan. Following this approval, it is expected that launch will take place in Japan in Q3, the companies said.

Theravance sees results from Salford COPD lung study in 2016"Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.

Radius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.

NephroGenex names Jaikrishna Patel as Chief Medical OfficerNephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.